Got Questions? Send us a message!

We explore whether two old antiparasitics, fenbendazole and ivermectin, can meaningfully impact cancer by disrupting cell structure, metabolism, and immune signaling while challenging how drugs get approved and funded. We lay out the science, question the incentives, and call for trials that prioritize survival and quality of life.

• Fenbendazole as a microtubule destabilizer leading to cell‑cycle arrest and apoptosis
• Potential to bypass efflux pump resistance and reduce glucose uptake
• Ivermectin triggering apoptosis, autophagy, and pyroptosis with immune activation
• Effects on proliferation, metastasis, and angiogenesis, plus synergy with chemotherapy
• The case for testing tumor stem cell vulnerability
• Regulatory critique around cost, profit incentives, and surrogate endpoints like PFS
• The limits of anecdotes and the need for rigorous, patient‑centered evidence
• Call for well‑designed phase II trials focused on OS and quality of life

For more on today's discussion, we invite you to visit fenbendersolhealth.org
Remember, the journey to health is personal and nuanced, so we encourage consulting with a healthcare professional before embarking on new health practices based on what you've discovered here
Always consult your physician before beginning any protocols
No information on this podcast is intended to diagnose, treat, or otherwise replace the opinion of medical professionals

FenbendazoleHelp.org and its informational resources are not intended to provide personal medical advice. Always consult your physician before beginning any protocols. No information on this site is intended to diagnose, treat, or otherwise replace the opinion of medical professionals. The purpose of this site is for informational purposes ONLY.